Brain Cancer News

Breaking News: FDA Approves Vorasidenib (Voranigo®)

A great day for Low Grade Astrocytoma and Oligodendroglioma Patients with IDH1/IDH2 Mutations

Aug 6, 2024 •

Scott L. Rakestraw, PhD

ASCO 2024: Brain Cancer Highlights

A few potential gems begin to sparkle

Jun 20, 2024 •

Scott L. Rakestraw, PhD

News: Erasca Reorganizes and Deprioritizes Development of ERAS-801 for rGBM

Yet Another EGFR-targeted Monotherapy Drops Anchor

May 17, 2024 •

Scott L. Rakestraw, PhD

Sam Blackman Speaks from the Heart

A personal account of bringing a new brain cancer medicine to patients

Apr 30, 2024 •

Scott L. Rakestraw, PhD

Breaking News: FDA Approves Tovorafenib (Ojemda®) for Pediatric LGG with BRAF Mutations

A Wonderful Day for pLGG patients and their families

Apr 23, 2024 •

Scott L. Rakestraw, PhD

AACR Brain Cancer Highlights

A tantalizing Phase 1 study of AZD-1390, some potential insights into poor CAR-T efficacy against solid tumors, and disappointing OS performance of…

Apr 11, 2024 •

Scott L. Rakestraw, PhD

Marizomib Fails a Phase 3 Clinical Trial in ndGBM Patients

Big Study. Muddy Biology. Ugh!

Mar 29, 2024 •

Scott L. Rakestraw, PhD

Novocure Reports METIS Top Line Clinical Trial Results for Brain Metastases from NSCLC

Promising, but we will wait for the full data presentation

Mar 27, 2024 •

Scott L. Rakestraw, PhD

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant Diffuse Glioma

News of Enormous Potential for IDH-mutant Glioma Patients

Feb 21, 2024 •

Scott L. Rakestraw, PhD

Another EGFRvIII-targeted Program BiTEs the Dust

Same As It Ever Was

Feb 1, 2024 •

Scott L. Rakestraw, PhD

MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma

Example of a transitional model for financing brain cancer therapeutics development

Jan 10, 2024 •

Scott L. Rakestraw, PhD

SNO Storm: Phase 3 Results for DCVax-L

Highlights from the Society for Neuro-Oncology (SNO) 2022 Annual Meeting

Nov 18, 2022 •

Scott L. Rakestraw, PhD

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts